At a glance
- Originator Taisho Pharmaceutical
- Class Neuroprotectants
- Mechanism of Action Cytochrome P 450 enzyme system inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Stroke in USA (Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Stroke in Japan (Injection)
- 30 Oct 2009 Pharmacodynamics data from animal studies in stroke presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)